FierceBiotech 30. März 2026 Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies
FierceBiotech 30. März 2026 Viridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincing
FierceBiotech 30. März 2026 Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial
FierceBiotech 30. März 2026 Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals
FierceBiotech 30. März 2026 Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025
FierceBiotech 30. März 2026 Biogen’s litifilimab sparkles in midphase lupus trial, raising hopes for pivotal readout
FierceBiotech 30. März 2026 Kardigan hypertension drug tangles biomarker win with blood pressure miss in phase 2 trial
FierceBiotech 30. März 2026 Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B
FierceBiotech 27. März 2026 Scientists turn pig semen extract into eye drops that kill cancer in mice
FierceBiotech 27. März 2026 'We need to put some bad ideas to bed': Inside Incubate's battles for biotech on Capitol Hill
FierceBiotech 27. März 2026 After local tumor approval, Novocure touts positive data in metastatic pancreatic cancer
FierceBiotech 27. März 2026 Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
FierceBiotech 27. März 2026 AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset